Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 6/20 | 0.34 |
| ▸ | CTSK | P43235 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3307105 | 0.85 | CYP3A4 (0.35) | SLC7A5ITGA4ITGB7LTA4HCA12 | |
| SCHEMBL855512 | 0.82 | SLC7A5 (0.44) | MEN1KMT2ASLC7A5ITGA4ITGB7 | |
| SCHEMBL28796517 | 0.80 | ACHE (0.43) | MEN1KMT2ASLC7A5LTA4HSYK | |
| SCHEMBL27847543 | 0.80 | SLC7A5 (0.45) | MEN1KMT2ASLC7A5ITGA4ITGB7 | |
| SCHEMBL27559984 | 0.78 | SLC7A5 (0.43) | SLC7A5LTA4H | |
| SCHEMBL5388891 | 0.77 | SLC7A5 (0.36) | MEN1KMT2ASLC7A5LTA4HCTSS | |
| SCHEMBL13546232 | 0.77 | SLC7A5 (0.40) | MEN1KMT2ASLC7A5ITGA4ITGB7 | |
| SCHEMBL5263832 | 0.76 | SLC7A5 (0.46) | MEN1KMT2ASLC7A5CTSSCTSK | |
| SCHEMBL3307232 | 0.76 | GLS (0.52) | CA12CA1CA7CA14 | |
| SCHEMBL27881041 | 0.75 | SLC7A5 (0.44) | MEN1KMT2ASLC7A5ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2128134-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | Shionogi&Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | MEN1 1275/4885KMT2A 2238/4885SLC7A5 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.